Johnson & Johnson (NYSE:JNJ) Shares Sold by Advisory Resource Group

Advisory Resource Group lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 96.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,218 shares of the company's stock after selling 32,284 shares during the period. Advisory Resource Group's holdings in Johnson & Johnson were worth $202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth about $29,000. Conquis Financial LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth about $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson in the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson during the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock traded down $0.92 during midday trading on Friday, hitting $149.81. 22,591,152 shares of the stock were exchanged, compared to its average volume of 7,993,824. The stock's 50-day moving average price is $154.07 and its 200-day moving average price is $153.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a market cap of $360.44 billion, a price-to-earnings ratio of 16.66, a PEG ratio of 2.27 and a beta of 0.42. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.47%. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is 57.84%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Raymond James Financial dropped their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, Barclays reduced their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.